Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
We are a profitable and growing company focused on the acquisition, development an...
We are a profitable and growing company focused...
We are a leading, rapidly growing synthetic biology company that has developed a d...
We are a leading, rapidly growing synthetic bio...
Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakal...
Correvio has two marketed, in-hospital, cardiol...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
Horizon is a biopharmaceutical company focused on researching, developing and comm...
Horizon is a biopharmaceutical company focused ...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Join the National Investor Network and get the latest information with your interests in mind.